COO

Business Profile & Competitive Position

The Cooper Companies, Inc. operates in the Healthcare sector, specifically the Medical – Instruments & Supplies industry, and runs two distinct medical-device divisions. CooperVision develops, manufactures and markets single-use, two-week and monthly contact lenses, plus specialty eye-care products such as silicone hydrogel lenses, orthokeratology and scleral lenses. CooperSurgical offers more than 600 products and services focused on fertility and women’s health, spanning gynecology, obstetrics, contraception, labor and delivery, cord-blood and tissue storage, IVF support, donor gametes, cryopreservation and genomic services.

On equity-return metrics alone, the competitive moat looks modest rather than dominant. Net margin is 5.6% and return on equity is just 2.8%, figures that suggest the company is reinvesting heavily, absorbing integration costs, or competing in segments where pricing power is limited despite a medically regulated product set. What supports a stronger intangible position is regulatory differentiation: MiSight 1 day is the only contact lens approved by the FDA, Chinese NMPA and Japanese MHLW to slow the progression of, and correct, myopia in age-appropriate children. With products sold in over 130 countries and roughly 500 R&D employees split across both segments, scale and approval breadth matter, but they have not yet translated into especially high profitability or capital efficiency.

Financial Posture

The Cooper Companies currently carries a market capitalization of $13.6 billion and trades at a price-to-earnings ratio of 59.2. That multiple is quite high relative to the company’s 5.6% net margin and 2.8% ROE, implying the market is pricing in a multi-year growth story rather than near-term cash generation. The stock’s beta is 0.82, meaning it has historically been less volatile than the broad market, which is consistent with a healthcare supplier operating in a largely non-discretionary area of medical consumption.

Investors should weigh that valuation carefully: a P/E above 50 combined with sub-3% ROE leaves little room for execution missteps. If CooperVision’s myopia platform or CooperSurgical’s fertility integrations deliver faster earnings growth, the premium can compress naturally through higher earnings; if not, the gap between price and current returns becomes the central risk.

Strategic Priorities & Outlook

The company’s most recent 10-K filing outlines four operational priorities. First, CooperVision is focused on greater worldwide market penetration of recently introduced products and on expanding its presence in both existing and emerging markets. Second, it is increasing investment in distribution and packaging capabilities to support business growth and quality service. Third, CooperVision is investing to develop the myopia-management market by educating eye-care practitioners, patients and their families. Fourth, CooperSurgical expects to continue investing in its business, including through strategic transactions, to expand its integrated-solutions model within fertility and women’s health.

Together these priorities point to a land-grain strategy: build share early in myopia management, lock in distribution scale, and use M&A to fill out CooperSurgical’s fertility and women’s-health ecosystem. That roadmap can drive top-line growth, but it also explains why near-term margins and ROE remain subdued.

Macro & Geopolitical Exposure

As a Healthcare / Medical – Instruments & Supplies company with global sales, Cooper faces a familiar set of macro forces. Regulatory approval risk is material in this industry: contact lenses and fertility devices must clear agencies such as the FDA, China’s NMPA and Japan’s MHLW, and changes in approval timelines or labeling can alter revenue trajectories. The company operates in over 130 countries, so currency translation, cross-border tariffs on medical devices, and regional reimbursement policies all feed into reported results.

Supply-chain inputs are another consideration. Contact-lens manufacturing depends on silicone hydrogel polymers, packaging materials and sterile distribution networks, any of which can be affected by commodity costs or logistics constraints. On the demand side, CooperVision is exposed to demographic trends in myopia prevalence, while CooperSurgical is exposed to fertility rates, healthcare access and insurance coverage for IVF and women’s-health procedures. None of these are company-specific surprises, but they are the standard macro and geopolitical variables that move a globally sourced medical-device supplier.

Recent Developments

The most recent headline directly tied to the COO ticker is a Zacks comparison on August 21, 2026, titled “COO vs. MMSI: Which Stock Is the Better Value Option?” which frames Cooper Companies against Merit Medical Systems. This tells us that, at the margin, sell-side commentary is asking whether Cooper’s valuation premium is justified relative to a peer medical-supply name.

Several other early-September headlines mention “COO,” but they concern the chief operating officer role at other companies, not Cooper Companies. On August 28, 2026, fool.com reported that Unity Software COO Alexander Blum sold 22,559 shares for roughly $1 million. A day earlier, on August 23, 2026, fool.com covered Rigetti Computing’s COO selling over 9,000 shares. Additionally, on August 19, 2026, gurufocus.com highlighted Target’s Q2 2026 earnings, including a 3.8% comparable-sales surge and raised full-year guidance. None of these directly affect Cooper’s operations, but they illustrate how the “COO” symbol can pull in unrelated chief-operating-officer news that is easy to misattribute.

Earnings Behavior & Post-Earnings Drift

Cooper Companies has beaten earnings estimates in all of the last eight reported quarters, an 8/8 beat rate, with an average surprise of 4.6%. Despite the consistency, the average five-day price move after those reports is -0.91%, classified as a downward post-earnings drift.

The last four quarters show how uneven that drift can be. On June 4, 2026, the company reported $1.21 versus an estimate of $1.10, a 10% surprise, and the stock rose 8.58% the next day and 8.85% over the following five sessions. On March 5, 2026, it reported $1.10 versus $1.03, a 6.8% beat, yet the stock fell 4.55% the next day and 10.82% over the next five days. On December 4, 2025, a $1.15 print against a $1.11 estimate, a 3.6% surprise, produced a 5.67% next-day gain and 6.59% five-day gain. But on August 27, 2025, a $1.10 result versus a $1.07 estimate, a 2.8% beat, was followed by a 12.86% drop the next day and an 8.24% five-day decline.

This pattern—reliable beats mixed with sharp negative reactions—suggests the market’s real expectation may be higher than the reported consensus. Beating by a few percent is not always enough when valuation is already priced for strong execution. The next report is scheduled for September 9, 2026 after the close, with a consensus EPS estimate of $1.12. At the current snapshot, the stock is at $69.87, below a 50-day EMA of $72.18, with an RSI of 35.5 that sits near oversold territory.

For a fuller picture of how institutional analysts are interpreting these numbers, valuation, and upcoming risk events, review the complete institutional verdict and consensus breakdown on the ticker page.